Tyra Biosciences Appoints Habib Dable to Board to Advance Dabogratinib Commercialization
Tyra Biosciences appointed Habib Dable, former Acceleron CEO and Bayer executive with a track record of launching EYLEA® and guiding Acceleron’s acquisition by Merck in 2021, to its Board to support commercialization of dabogratinib in LG-UTUC, IR NMIBC and ACH. Gilla Kaplan will conclude her board service at the 2026 annual meeting.
1. Appointment of Habib Dable
On April 17, 2026, Tyra Biosciences announced the addition of Habib Dable to its Board of Directors. His role will focus on guiding the company through its next growth phase, particularly as it prepares for the commercial launch of its lead FGFR3 inhibitor, dabogratinib.
2. Leadership Track Record
Dable brings over 30 years of biopharmaceutical leadership, having served as President and CEO of Acceleron Pharma during its acquisition by Merck in 2021, and in senior roles at Bayer where he oversaw the global launch of EYLEA® and led U.S. Pharmaceuticals.
3. Implications for Pipeline
His strategic expertise in building blockbuster franchises and executing global product launches is expected to accelerate Tyra’s 3x3 multi-indication strategy, enhancing the commercial prospects of dabogratinib for LG-UTUC, IR NMIBC and achondroplasia, as well as other FGFR-targeted programs.
4. Board Transition
In conjunction with Dable’s appointment, long-serving director Gilla Kaplan will step down at the upcoming 2026 annual meeting, marking a planned transition that aligns with Tyra’s shift from early-stage development to commercialization readiness.